Ungar Andrea, Fumagalli Stefano, Marini Maurizio, Di Serio Claudia, Tarantini Francesca, Boncinelli Lorenzo, Baldereschi Giorgio, Valoti Paolo, La Cava Giuseppe, Olianti Catia, Masotti Giulio, Marchionni Niccolò
Department of Critical Care Medicine and Surgery, Unit of Gerontology and Geriatric Medicine, University of Florence and Azienda Ospedaliera Careggi, Florence, Italy.
Crit Care Med. 2004 May;32(5):1125-9. doi: 10.1097/01.ccm.0000124871.58281.d1.
To determine whether the short-term systemic and renal hemodynamic response to dopamine is influenced by clinical severity of congestive heart failure.
Effects of increasing doses of dopamine were assessed in patients consecutively admitted for acutely decompensated congestive heart failure.
Intensive care unit.
We enrolled 16 congestive heart failure patients stratified by clinical severity (New York Heart Association [NYHA] class III, n = 8; NYHA class IV, n = 8) and two additional NYHA class III patients as controls.
Measurements were carried out throughout five 20-min experimental periods: baseline, dopamine infusion at 2, 4, and 6 microg x kg(-1) x min(-1), and recovery. Controls received a similar amount of saline.
Systemic and renal hemodynamics were determined respectively by right cardiac catheterization and radioisotopes (iodine 131-labeled hippuran and iodine 125-labeled iothalamate clearance). The peak increase in heart rate and cardiac index occurred at a dopamine dose of 4-6 microg x kg(-1) x min(-1). The dose-response relation was similar in NYHA classes III and IV. Improvement in effective renal plasma flow and glomerular filtration rate, peaking at 4 microg x kg(-1) x min(-1), was more rapid and marked in NYHA class III than class IV patients, in whom the renal fraction of cardiac output failed to increase. The systemic and renal effects of dopamine were independent of age. No change occurred in controls.
The dose of dopamine producing an optimal improvement of systemic and renal hemodynamics in congestive heart failure is higher than usually reported. A greater clinical severity of congestive heart failure impairs the renal effects of dopamine, probably through a selective loss in renal vasodilating capacity.
确定多巴胺的短期全身及肾脏血流动力学反应是否受充血性心力衰竭临床严重程度的影响。
对因急性失代偿性充血性心力衰竭连续入院的患者评估递增剂量多巴胺的作用。
重症监护病房。
我们纳入了16例根据临床严重程度分层的充血性心力衰竭患者(纽约心脏协会[NYHA]Ⅲ级,n = 8;NYHAⅣ级,n = 8),并另外纳入2例NYHAⅢ级患者作为对照。
在五个20分钟的实验阶段进行测量:基线期、多巴胺以2、4和6微克·千克⁻¹·分钟⁻¹的速度输注期以及恢复期。对照组输注等量生理盐水。
分别通过右心导管检查和放射性同位素(碘131标记的马尿酸盐和碘125标记的碘他拉酸盐清除率)测定全身及肾脏血流动力学。心率和心脏指数的峰值增加出现在多巴胺剂量为4 - 6微克·千克⁻¹·分钟⁻¹时。NYHAⅢ级和Ⅳ级患者的剂量反应关系相似。有效肾血浆流量和肾小球滤过率的改善在4微克·千克⁻¹·分钟⁻¹时达到峰值,NYHAⅢ级患者比Ⅳ级患者更迅速且显著,Ⅳ级患者的心输出量肾部分未能增加。多巴胺的全身和肾脏作用与年龄无关。对照组未发生变化。
在充血性心力衰竭中产生全身和肾脏血流动力学最佳改善的多巴胺剂量高于通常报道的剂量。充血性心力衰竭更严重的临床状况会损害多巴胺的肾脏作用,可能是通过肾血管舒张能力的选择性丧失。